Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs - PubMed (original) (raw)
Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs
L A García-Rodríguez et al. Epidemiology. 2001 Jan.
Abstract
Use of nonsteroidal antiinflammatory drugs (NSAIDs) has been associated with a reduced risk of colorectal cancer, but limited information is available on the effect of individual nonaspirin NSAIDs. In addition, the dose-response relation of aspirin in reducing the risk of colorectal cancer has not been described. We carried out a population-based cohort study with secondary case-control analysis to determine the association between the risk of colorectal cancer and use of aspirin and individual NSAIDs, including the role of dose and duration. The General Practice Research Database in the U.K. was the source population. We traced 943,903 persons 40-79 years of age and free of cancer and colorectal adenoma between January 1994 and September 1997. A total of 2,002 incident cases of colorectal cancer were ascertained. The incidence rate of colorectal cancer per 10,000 person-years was 7.3. The risk of colorectal cancer was reduced in users of nonaspirin NSAIDs and became evident after 6 months of continuous treatment. The adjusted relative risk was 0.5 (95% confidence interval = 0.4-0.7). The reduction in risk disappeared completely 1 year after stopping NSAID treatment. The risk of developing colorectal cancer was reduced in long-term users of aspirin at doses of 300 mg daily (relative risk = 0.6; 95% confidence interval = 0.4-0.9). Daily doses of 75 and 150 mg aspirin were not associated with a reduced risk of colorectal cancer. Our data support the existence of an important protective effect of nonaspirin NSAID continuous intake against colorectal cancer and point to a similar reduction in risk for aspirin at doses of at least 300 mg daily. One-year treatment with NSAIDs would prevent one case of colorectal cancer in a population of 1,000 persons 70-79 years of age.
Comment in
- Colorectal cancer among users of aspirin and non-steroidal antiinflammatory drugs.
Chambers S, Evans L, Krishnan A. Chambers S, et al. Epidemiology. 2001 Jul;12(4):471-2. doi: 10.1097/00001648-200107000-00020. Epidemiology. 2001. PMID: 11416786 No abstract available.
Similar articles
- Reduced incidence of colorectal adenoma among long-term users of nonsteroidal antiinflammatory drugs: a pooled analysis of published studies and a new population-based study.
García Rodríguez LA, Huerta-Alvarez C. García Rodríguez LA, et al. Epidemiology. 2000 Jul;11(4):376-81. doi: 10.1097/00001648-200007000-00003. Epidemiology. 2000. PMID: 10874542 - Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drug Use and Colorectal Cancer Risk: A Population-Based, Case-Control Study.
Friis S, Riis AH, Erichsen R, Baron JA, Sørensen HT. Friis S, et al. Ann Intern Med. 2015 Sep 1;163(5):347-55. doi: 10.7326/M15-0039. Ann Intern Med. 2015. PMID: 26302241 - Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer.
Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Curhan GC, Fuchs CS. Chan AT, et al. JAMA. 2005 Aug 24;294(8):914-23. doi: 10.1001/jama.294.8.914. JAMA. 2005. PMID: 16118381 Free PMC article. - Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force.
Rostom A, Dubé C, Lewin G, Tsertsvadze A, Barrowman N, Code C, Sampson M, Moher D; U.S. Preventive Services Task Force. Rostom A, et al. Ann Intern Med. 2007 Mar 6;146(5):376-89. doi: 10.7326/0003-4819-146-5-200703060-00010. Ann Intern Med. 2007. PMID: 17339623 Review. - Aspirin, non-steroidal anti-inflammatory drugs and protection from colorectal cancer: a review of the epidemiological evidence.
Weiss HA, Forman D. Weiss HA, et al. Scand J Gastroenterol Suppl. 1996;220:137-41. doi: 10.3109/00365529609094766. Scand J Gastroenterol Suppl. 1996. PMID: 8898452 Review.
Cited by
- Expression analysis of lymphocyte subsets and lymphocyte-to-monocyte ratio: reveling immunosuppression and chronic inflammation in breast cancer.
Zhang H, Li Y, Liu G, Chen X. Zhang H, et al. J Cancer Res Clin Oncol. 2024 Jan 23;150(1):28. doi: 10.1007/s00432-023-05508-1. J Cancer Res Clin Oncol. 2024. PMID: 38263363 Free PMC article. - Correlation between expression of cyclooxygenase-2 and angiogenesis in human gastric adenocarcinoma.
Li HX, Chang XM, Song ZJ, He SX. Li HX, et al. World J Gastroenterol. 2003 Apr;9(4):674-7. doi: 10.3748/wjg.v9.i4.674. World J Gastroenterol. 2003. PMID: 12679908 Free PMC article. - [Epidemiological studies for evaluating the role of cyclooxygenase in chemoprevention of malignant tumors].
Schernhammer ES, Dittrich C. Schernhammer ES, et al. Wien Med Wochenschr. 2003;153(5-6):104-15. doi: 10.1046/j.1563-258x.2003.03004.x. Wien Med Wochenschr. 2003. PMID: 12705063 Review. German. - Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies.
Huxley R, Ansary-Moghaddam A, Berrington de González A, Barzi F, Woodward M. Huxley R, et al. Br J Cancer. 2005 Jun 6;92(11):2076-83. doi: 10.1038/sj.bjc.6602619. Br J Cancer. 2005. PMID: 15886696 Free PMC article. - Rheumatology and musculoskeletal medicine.
Davenport G; Primary Care Rheumatology Society Steering Committee. Davenport G, et al. Br J Gen Pract. 2004 Jun;54(503):457-64. Br J Gen Pract. 2004. PMID: 15186570 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical